ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2932

mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG

Jérôme Hadjadj1, Guillaume Canaud2, Tristan Mirault3, Maxime Samson4, Patrick Bruneval5, Alexis Regent6, Claire Goulvestre7, Veronique Witko-Sarsat8, Nathalie Costedoat-Chalumeau9, Loïc Guillevin for the French Vasculitis Study Group10, Luc Mouthon11 and Benjamin Terrier12, 1Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, Paris, France, Paris, France, 2Department of Nephrology and Transplantation, Necker-Enfants Malade, Université Paris Descartes, Sorbonne Paris Cité, INSERM U1151, Necker-Enfants Malades Hospital, Paris, France AP-HP, Paris, France, PARIS, France, 3Department of Vascular Medicine, Georges Pompidou European Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, Paris, France, 4Dijon University Hospital, Dijon, France, 5HEGP, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 7Department of Immunology, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 8Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, LABEX Inflamex, Université Sorbonne Paris Cité, 75013, Paris, France, Paris, France, 9Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, 10Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 11Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, 12Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: giant cell arteritis, mTor, takayasu arteritis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 8, 2017

Title: Vasculitis III: Pathogenesis

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells, leading to ischemic events. We hypothesized that mammalian target of rapamycin (mTOR) pathway could drive vascular inflammation and remodelling in large-vessel vasculitis.

Methods: To study activation of mTOR pathway in injured vessels from patients with TA and GCA, we evaluated phosphorylation of S6RP (p-S6RP) and AKT (p-AKT Ser 473) by immunofluorescence analysis on aorta and temporal arteries biopsies, which reflect activation of mTORC1 and mTORC2, respectively. To investigate the potential role of antibodies binding to ECs in the activation of mTOR pathway, sera from patients with TA, GCA and healthy controls (HCs) were screened for the presence of antibodies against ECs (AECA) using indirect immunofluorescence (IIF) and cellular ELISA. We evaluated in vitro the effect of purified IgG from patients with AECA on mTOR pathway activation and cell proliferation. Target antigens of AECA were investigated by Western-blotting.

Results: Immunofluorescence analysis on tissues revealed that adventitial vessels from aorta’s vasa vasorum from TA patients were strongly positive for both p-S6RP and p-AKT (Ser 473) in ECs but not in vascular smooth muscle cells, showing that both mTORC1 and mTORC2 were specifically activated in ECs in TA, but not in ECs from GCA patients and HCs (Figure 1). Using IIF and cellular ELISA, we observed higher levels of AECA in TA patients compared to GCA and healthy controls (HCs) with these two techniques. Using Western blot, we demonstrated that purified IgG from TA patients caused mTORC1 activation in ECs, whereas this effect was not observed with purified IgG from GCA or HCs. mTORC1 was activated through PI3K-AKT pathway, suggesting that recruitment of AKT to the cell membrane is necessary for activation of the mTOR pathway induced by serum IgG in TA. Finally, purified IgG from TA induced a significant ECs proliferation compared to GCA and HCs IgG, and this effect was decreased after ECs exposure with sirolimus, a specific mTOR inhibitor, and PI3K inhibitor. Sera obtained from TA patients with positive screening of AECA bound predominantly to an endothelial cell antigen with a molecular weight between 60 and 65 kDa.

Conclusion: Our results suggest that antibodies against ECs drive vascular inflammation leading then to vascular remodelling in TA through activation of mTOR pathway in ECs, but not in GCA. Inhibition of mTOR pathway could represent an alternative therapeutic option in TA.

Figure 1 :


Disclosure: J. Hadjadj, None; G. Canaud, None; T. Mirault, None; M. Samson, None; P. Bruneval, None; A. Regent, None; C. Goulvestre, None; V. Witko-Sarsat, None; N. Costedoat-Chalumeau, None; L. Guillevin for the French Vasculitis Study Group, None; L. Mouthon, None; B. Terrier, None.

To cite this abstract in AMA style:

Hadjadj J, Canaud G, Mirault T, Samson M, Bruneval P, Regent A, Goulvestre C, Witko-Sarsat V, Costedoat-Chalumeau N, Guillevin for the French Vasculitis Study Group L, Mouthon L, Terrier B. mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/mtor-pathway-is-activated-in-endothelial-cells-from-patients-with-takayasu-arteritis-and-is-modulated-by-serum-igg/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mtor-pathway-is-activated-in-endothelial-cells-from-patients-with-takayasu-arteritis-and-is-modulated-by-serum-igg/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology